Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.83 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
| ▸ | FBP1 | P09467 | 1/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.83 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.83 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.83 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.83 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.83 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8836314 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL8862541 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL31448299 | 1.00 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL24145382 | 0.92 | P2RX1 (0.80) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL9394807 | 0.92 | P2RX1 (0.80) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL22381966 | 0.92 | NT5E (0.80) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL22402643 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL22393014 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL26361720 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 | |
| SCHEMBL8862549 | 0.92 | P2RY1 (0.83) | P2RY1P2RY2SRCSMN1; SMN2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | ALNYLAM PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3578656-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3693463-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200231968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | ALNYLAM PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3052628-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3249052-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | BANK OF AMERICA, N.A. | 2018-05-10 | — | — | US | disclosed |
| EP-3249052-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170121709-A1 | Compositions and Methods for Inhibiting Expression of Factor V | ALNYLAM PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | ALNYLAM PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | BANK OF AMERICA, N.A. | 2006-05-18 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-5700786-A | Analogues of adenosine 5'diphosphate and pharmaceutical compositions thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-12-23 | — | — | US | disclosed |
| US-5658890-A | INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-08-19 | — | — | US | disclosed |
| US-5569650-A | C-nucleoside isosters of analogs thereof and pharmaceutical compositions | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-10-29 | — | — | US | disclosed |
| WO-1994029331-A1 | NICOTINAMIDE RIBONUCLEOTIDE ISOSTERS, ISOSTERIC NAD ANALOGUES. THEIR SYNTHESES AND USE IN TREATMENTS OF ALCOHOLISM AND NEOPLASTIC DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210189393-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | F5, F13B, F13A1 | P2RY1 4225/4885P2RY2 3732/4885SRC 4428/4885 |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | APOB, LDLR, APOL1 | P2RY1 4627/4885P2RY2 4646/4885SRC 3654/4885 |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | GEMIN5, RNASE1, EFTUD2 | P2RY1 4616/4885P2RY2 4472/4885SRC 4733/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | P2RY1 4470/4885P2RY2 4430/4885SRC 4524/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | P2RY1 4678/4885P2RY2 4519/4885SRC 4753/4885 |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | HTT, HYPK, DHX36 | P2RY1 3828/4885P2RY2 3692/4885SRC 4051/4885 |
| US-20200231968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V | F5, F13B, F13A1 | P2RY1 4225/4885P2RY2 3732/4885SRC 4428/4885 |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | P2RY1 4802/4885P2RY2 4793/4885SRC 4676/4885 |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | F5, F13B, F13A1 | P2RY1 4225/4885P2RY2 3732/4885SRC 4428/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | P2RY1 657/4885P2RY2 624/4885SRC 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.